HISAMITSU PHARM CO
PharmaHISAMITSU PHARM CO is a pharmaceutical company focused on Immunology. Key products include SECUADO.
HISAMITSU PHARM CO at a Glance
- Strong track record with 100% execution quality across 6 trials
- Fast trial execution (10 months median completion)
HISAMITSU PHARM CO's Key Drugs
HISAMITSU PHARM CO's core commercial portfolio centers on SECUADO, spanning Immunology — its most strategically important drugs approved in the last 15 years.
HISAMITSU PHARM CO's Recent FDA Approvals
New NDA/BLA approvals for HISAMITSU PHARM CO over the last two years — novel drugs only, excluding generics and label supplements.
HISAMITSU PHARM CO's Therapeutic Areas
HISAMITSU PHARM CO's approved drugs and pipeline span 1 therapeutic area, led by Immunology, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
HISAMITSU PHARM CO's Top Competitors
HISAMITSU PHARM CO's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
HISAMITSU PHARM CO Pipeline Snapshot
HISAMITSU PHARM CO has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SECUADO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 3/3 completed
- • Speed: 10 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2008-02-20
- Latest
- 2025-10-06
- Applications
- 2
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges